Literature DB >> 18070214

Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: a population-based study.

J Schmitt1, M Meurer, M Klon, K D Frick.   

Abstract

BACKGROUND: Health utilities are used to express relevant trade-offs for resource allocation. The absence of valid and generalizable utilities for atopic eczema (AE) and psoriasis limits the validity of previous cost-utility analyses.
OBJECTIVES: (i) To assess health utilities of standardized scenarios of controlled and uncontrolled AE and psoriasis in participants from the general population and in patients using the time trade-off (TTO) method; (ii) to test the association of the utilities obtained with demographic and patient characteristics; and (iii) to compare these utilities with other health economic outcomes [utilities assessed on visual analogue scale (VAS), willingness to pay (WTP)].
METHODS: A single-centre study conducted in 2006 at the Department of Dermatology, Dresden, Germany. Standardized interactive computer-assisted interviews in a random sample from the general population (n=139), and patients with AE (n=58) and psoriasis (n=62). Information on health states included characteristic clinical pictures and a short text explaining aetiology, signs, symptoms and quality of life impact.
RESULTS: In participants from the general population median utilities (TTO) of controlled and uncontrolled AE were 0.97 and 0.64, respectively. For psoriasis the corresponding utilities were 0.93 and 0.56. Utilities were independent of sex and socioeconomic position, and tended to be lower in patients with psoriasis. Correlations between TTO, VAS and WTP responses were weak.
CONCLUSIONS: To avoid uncontrolled psoriasis or eczema participants chose an approximately 40% shorter life expectancy. This indicates that severe chronic inflammatory skin diseases may be considered as severe as angina pectoris, chronic anxiety, rheumatoid arthritis, multiple sclerosis or regional oesophageal cancer. The different economic outcomes assessed are not interchangeable.

Entities:  

Mesh:

Year:  2007        PMID: 18070214     DOI: 10.1111/j.1365-2133.2007.08354.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  18 in total

Review 1.  [Health services research in dermatology. Current status].

Authors:  N Franzke; M Augustin
Journal:  Hautarzt       Date:  2011-03       Impact factor: 0.751

2.  [Health services research the example of atopic dermatitis].

Authors:  J Schmitt
Journal:  Hautarzt       Date:  2011-03       Impact factor: 0.751

3.  Cost-Effectiveness Analysis of Ixekizumab vs Etanercept and Their Manufacturer-Recommended Dosing Regimens in Moderate to Severe Plaque Psoriasis.

Authors:  Jeremy Udkoff; Lawrence F Eichenfield
Journal:  J Drugs Dermatol       Date:  2017-10-01       Impact factor: 2.114

4.  Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response - results of a phase II regimen-finding trial.

Authors:  M Augustin; S Abeysinghe; U Mallya; A Qureshi; N Roskell; D McBride; C Papavassillis; J Gelfand
Journal:  J Eur Acad Dermatol Venereol       Date:  2015-12-10       Impact factor: 6.166

Review 5.  A review of health utilities across conditions common in paediatric and adult populations.

Authors:  Jean-Eric Tarride; Natasha Burke; Matthias Bischof; Robert B Hopkins; Linda Goeree; Kaitryn Campbell; Feng Xie; Daria O'Reilly; Ron Goeree
Journal:  Health Qual Life Outcomes       Date:  2010-01-27       Impact factor: 3.186

6.  Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States.

Authors:  Reginald Villacorta; Joel W Hay; Andrew Messali
Journal:  Pharmacoeconomics       Date:  2013-09       Impact factor: 4.981

7.  Measuring melasma patients' quality of life using willingness to pay and time trade-off methods in Thai population.

Authors:  Charussri Leeyaphan; Rungsima Wanitphakdeedecha; Woraphong Manuskiatti; Kanokvalai Kulthanan
Journal:  BMC Dermatol       Date:  2011-12-19

8.  It is not always about gains: utilities and disutilities associated with treatment features in patients with moderate-to-severe psoriasis.

Authors:  Nasir Umar; Ina Schöllgen; Darcey D Terris
Journal:  Patient Prefer Adherence       Date:  2012-03-15       Impact factor: 2.711

9.  Acute and chronic impact of cardiovascular events on health state utilities.

Authors:  Louis S Matza; Katie D Stewart; Shravanthi R Gandra; Philip R Delio; Brett E Fenster; Evan W Davies; Jessica B Jordan; Mickael Lothgren; David H Feeny
Journal:  BMC Health Serv Res       Date:  2015-04-22       Impact factor: 2.655

10.  Health state utilities associated with attributes of treatments for hepatitis C.

Authors:  Louis S Matza; Sandhya J Sapra; John F Dillon; Anupama Kalsekar; Evan W Davies; Mary K Devine; Jessica B Jordan; Amanda S Landrian; David H Feeny
Journal:  Eur J Health Econ       Date:  2014-12-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.